Recursion Pharmaceuticals, Inc. (RXRX) Financials
RXRX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 653.7 million | 190.3 million |
2023-09-30 | 630.8 million | 192.9 million |
2023-06-30 | 666.7 million | 197.7 million |
2023-03-31 | 627.4 million | 197.2 million |
RXRX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -76.5 million | 16.1 million |
2023-09-30 | -73.7 million | 16.8 million |
2023-06-30 | -71.4 million | 11.8 million |
2023-03-31 | -78.7 million | 8.8 million |
RXRX Net Income
No data available :(
RXRX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 394.8 million | - | 49.5 million |
2023-09-30 | 387.3 million | - | 49.7 million |
2023-06-30 | 405.9 million | 1.2 million | 51.1 million |
2023-03-31 | 473.1 million | 1.2 million | 51.2 million |
RXRX Shares Outstanding
RXRX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 2.4 million | 66.1 million | 30.5 million | - |
2023-09-30 | 827000 | 70.0 million | 29.2 million | - |
2023-06-30 | 4.0 million | 55.1 million | 28.3 million | - |
2023-03-31 | 5.3 million | 46.7 million | 22.9 million | - |
RXRX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 10.9 million | 23.5 million |
2023-09-30 | 10.1 million | 10.9 million |
2023-06-30 | 11.0 million | 9.4 million |
2023-03-31 | 12.1 million | 12.4 million |
RXRX
Price: $9.08
52 week price:
Earnings Per Share: -1.58 USD
P/E Ratio: -6.25
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 732400
Market Capitalization: 2.1 billion